$0.38
-0.01 (-3.76%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where SNGX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
11 interventional · 7 with posted results
Held by 2 tracked-famous managers (CITADEL ADVISORS LLC, JANE STREET GROUP, LLC) · FINRA short interest 1.8 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCLNCT06470451Number of Participants with a Treatment Response in the Modified Composite Assessment of Index Lesion Disease Severity (mCAILS) scoreRandomized · Quadruple-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: The Data Monitoring Committee conducted an interim analysis and recommended that the study be halted for futility | Drug: Hypericin, Placebo | CTCL/ Mycosis Fungoides, CTCL, Mycosis Fungoides, Cutaneous T Cell Lymphoma | 70 | 2026-05-22actual | 2026-07-13 |
| Topical SGX302 for Mild-to-Moderate PsoriasisNCT05442190Number of patients that achieve a 0 or 1 score using the 5-point Investigator's Global Assessment scaleRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Hypericin | Psoriasis, Plaque Psoriasis, Psoriasis Vulgaris | 15 | 2025-10-22actual | 2026-08-13 |
| Dusquetide for the Treatment of Behcet's DiseaseNCT06386744Number of Oral UlcersOpen-label · Treatment | Phase 2 | Completed | Drug: Dusquetide | Behçet Disease | 8 | 2025-05-23actual | 2025-08-01 |
| HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCLNCT06149247results2025-08-20Number of Participants With a Treatment Response in the Modified Composite Assessment of Index Lesion Disease Severity (mCAILS) ScoreRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Hypericin, Mechlorethamine Topical Gel | Cutaneous T-Cell Lymphoma/Mycosis Fungoides | 10 | 2024-05-31actual | 2025-08-20 |
| PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell LymphomaNCT05380635results2023-06-07Electrocardiograms (ECG)Open-label · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Hypericin | Cutaneous T-Cell Lymphoma/Mycosis Fungoides | 9 | 2022-08-16actual | 2023-06-07 |
| FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)NCT02448381results2022-04-15Number of Responders and Non-Responders With a Treatment Response in 3 Treated Lesions as Defined as a ≥50% Improvement in the Composite Assessment of Index Lesion Disease Severity (CAILS) Score When Compared to Patients Receiving PlaceboRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: SGX301 (synthetic hypericin), Placebo | Cutaneous T-Cell Lymphoma | 169 | Jun 2020actual | 2022-04-15 |
| DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck CancerNCT03237325results2022-08-29Duration of Severe Oral Mucositis (SOM)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: SGX942, Placebo | Squamous Cell Carcinoma of the Oral Cavity and Oropharynx, Oral Mucositis | 266 | 2020-06-24actual | 2022-11-08 |
| A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck CancerNCT02013050results2017-07-31Duration of Severe Oral Mucositis (SOM)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: SGX942, Placebo | Oral Mucositis | 111 | Dec 2015actual | 2017-08-28 |
| Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)NCT01925950results2018-10-04Gastrointestinal (GI) Graft-vs-Host Disease (GVHD) SymptomsRandomized · Quadruple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: The study was stopped due to patient enrollment challenges. | Drug: orBec, Placebo | Chronic Gastrointestinal Graft vs Host Disease | 2 | May 2015actual | 2018-11-01 |
| A Dose Ranging Study of Delayed Release Beclomethasone for Prevention of Acute Enteritis in Patients With Rectal CancerNCT01073384Preliminary EfficacyRandomized · Open-label · Prevention | Phase 1/2 | Completed | Drug: SGX201 (delayed release beclomethasone 17,21-dipropionate) | Enteritis | 16 | Jan 2012actual | 2012-12-17 |
| Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)NCT00926575results2013-12-06The Proportion of Subjects With GVHD Treatment FailureRandomized · Quadruple-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: An independent Data Safety Monitoring Board recommended the study be stopped due to futility | Drug: oral beclomethasone 17,21-dipropionate, Placebo | Acute Gastrointestinal Graft vs Host Disease | 140 | Dec 2011actual | 2013-12-06 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19